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Abstract
Introduction: Anemia is the most frequent hematological disturbance in cancer patients, with prevalence between 30% and 
90%, depending on the type of tumor, the antitumor treatment, and other factors (infection, malnutrition, bleeding, tumor 
inﬁ  ltration of the bone marrow). A number of erythropoietic agents have shown to be effective in increasing the hemoglobin 
(Hb) levels, reducing the requirements for transfusion, and improving quality of life. The objective of this study is to com-
pare darbepoetin alfa and epoetin alfa when used to correct anemia in cancer patients who are receiving radiotherapy or 
radiochemotherapy. 
Material and methods: A prospective study of 125 consecutive patients with anemia (Hb  13 g/dL in males or  12 g/dL 
in females) who were undergoing treatment with radiotherapy (RT) or radiochemotherapy (RCT) in our department were 
enrolled between March 2003 and March 2005. The treatment for the anemia was either darbepoetin alfa 150 mcg/week 
(62 patients, group 1) or epoetin alfa 40,000 IU/week (63 patients, group 2). Patients received iron supplements in both 
groups. Treatment was administered in a consecutive manner depending on tumor type. If the increase in Hb was  1 g/dL 
after 4 weeks of treatment, the dose was increased to 300 mcg/week in group 1 or to 60,000 IU/week in group 2. The treat-
ment was terminated when a Hb value of  15 g/dL was reached during RT treatment, a Hb value of  14 g/dL was reached 
if the RT had been completed, or after 16 weeks of treatment whatever the Hb value. The mean age of patients was 
63.36 ± 11.27 years, 67% were male. No signiﬁ  cant differences were observed between the 2 groups in tumor type or stage, 
previous treatments, or intent to treat with RT or RCT. 
Results: Comparing group 1 and group 2 by intent to treat, the mean Hb at the start of treatment with the study drug was 
12.1 g/dL vs 11.8 g/dL, the proportion of patients whose dose was increased was19.7% vs 24.6%, the need for transfusion 
was 3.2% in each group, the duration of erythropoietic treatment was 6.5 weeks in both groups, and 2 patients in group 2 
restarted treatment with epoetin alfa. The percentage of patients who responded (deﬁ  ned as an increase in the Hb   2 g/dL 
in the absence of transfusions) was of 72.6% and 66.7%, respectively. Four vascular adverse events were observed, 2 in 
each group. No signiﬁ  cant differences were observed with respect to the baseline, week 4, and week 12 levels of endogenous 
erythropoietin, serum iron,% saturation, and ferritin. The increase in Hb 1 month after the ﬁ  nal administration of the study 
drug was 2.21 g/dL in group 1 and 2.46 g/dL in group 2 (p = ns). 
Conclusions: The results of our study demonstrate that both treatments are equally effective in correcting anemia in cancer 
patients undergoing RT or RCT.
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Introduction
Anemia is present in 30% to 90% of cancer patients, depending on the type of tumor and on the deﬁ  ni-
tion of anemia used (1). Its origin is multifactorial: chronic inﬂ  ammation, blood loss, nutritional deﬁ  cits, 
hemolysis, bone marrow inﬁ  ltration by malignant cells, low erythropoietin levels, and a reduction in 
the response to erythropoietin (2). Furthermore, most oncological treatments cause anemia (3). Anemia 
increases tumor hypoxia, which is common in patients with anemia, may increase the aggressive behav-
ior of the tumor and reduce the efﬁ  cacy of radiotherapy (4–6), and is therefore a prognostic factor for 
local control and survival (7–11).394
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The current treatment of anemia in cancer 
patients is the administration of erythropoiesis-
stimulating factors. In cases of severe anemia, 
red blood cell (RBC) transfusions may also be 
used. Transfusions provide a rapid correction of 
anemia but are associated with a series of risks 
such as acute transfusion reactions and possible 
infections (12).
Recombinant human erythropoietin (rHuEPO) 
is a protein that stimulates erythropoiesis and is 
effective in the prevention and reversal of anemia 
in patients with cancer (13). Darbepoetin alfa also 
stimulates erythropoiesis and has a longer serum 
half-life than rHuEPO. Darbepoetin alfa can be 
used in various doses and regimens including 
administration every 1, 2, or 3 weeks. It is well 
tolerated and effective for the treatment of anemia 
in cancer patients (14,15).
The objective of this study was to compare 
darbepoetin alfa with epoetin alfa, both adminis-
tered weekly, for the correction of anemia in can-
cer patients undergoing radiotherapy (RT) or 
radiochemotherapy (RCT) treatment.
Material and Methods
We performed a prospective study, between 
March 2003 and March 2004, that included 125 
consecutive patients with anemia, deﬁ  ned as a 
Hb   13 g/dL in males or  12 g/dL in females. 
These patients were undergoing either RT or 
RCT in our department. Basal endogenous eryth-
ropoietin (EPO) levels and iron metabolism were 
measured at baseline and during the 4th and 12th 
weeks; and a weekly blood count was measured 
during RT or RCT treatment and one month after 
the ﬁ  nal dose of the study drug. Two treatment 
groups were established: group 1, darbepoetin 
alfa 150 mcg/week; and group 2, epoetin alfa 
40.000 IU/week. Oral iron supplements were 
given to patients in both groups. If the Hb 
increase was  1 g/dL after 4 weeks of treatment, 
the dose was increased to 300 mcg/week in 
group 1 or to 60.000 IU/week in group 2. The 
treatment was suspended if Hb values  15 g/dL 
were reached during RT or RCT treatment, if 
values  14 g/dL were reached after completing 
the RT or RCT, or after 16 weeks of treatment 
regardless of the Hb level. RBC transfusion was 
indicated if the Hb value fell below 8 g/dL. 
Assignment to treatment groups was made in a 
consecutive manner according to the tumor type: 
62 patients were assigned to group 1 and 
63 patients to group 2. The mean age overall was 
63.36 ± 11.27 years, and 67% were males. The 
descriptive characteristics of the sample are 
presented in Table 1. Both groups well are bal-
anced and not statistically signiﬁ  cant differences 
were observed between the groups with respect 
to age, tumor type or stage, previous oncological 
treatment, or current oncological treatment: RT 
or RCT and intent to treat with RT.
The following variables were analyzed:
•  the changes in Hb levels,
•    the proportion of patients who doses were 
increased,
•    the percentage of patients who responded 
(deﬁ  ned as an increase in Hb of  2 g/dL in the 
absence of RBC transfusions),
•  the duration of treatment with the study drug,
•  the transfusion requirements,
•  the changes in iron metabolism, and
•  the onset of adverse events.
The SPSS version 12.0 program was used for 
the statistical analysis. The results are presented 
by intent to treat. The descriptive statistic of 
the sample has been made as well as comparison 
of the groups by means of the ANOVA test, Χ2 
de Pearson, and univariante analysis to determine 
the factors that inﬂ  uence in the response to the 
treatment. The p meaning level has been 
considered   to 0.05.
Results
The mean levels of endogenous EPO were of 
45.03 ± 44.02 mU/mL (95% conﬁ  dence interval 
of the mean: 37.04 to 53.02 mU/mL). No statisti-
cally significant differences were observed 
between treatment groups (p = 0.076). The mean 
Hb level at the start of treatment with the study 
drug was 11.85 ± 1.12 g/dL in group 1 and 11.76 ± 
1.13 g/dL in group 2 (p = 0.651). After 4 weeks 
of treatment, the Hb levels had increased in both 
groups: 13.16 ± 1.7 g/dL in group 1 and 13.02 ± 
1.93 g/dL in group 2 (p = 0.320). The weekly 
changes in the Hb levels are shown in Figure 1. 
In group 1, the darbepoetin alfa dose was doubled 
in 12 patients (19.4%). The epoetin alfa dose was 
doubled in 15 patients (23.8%) in group 2 
(p = 0.667). During the study, 2 patients (3.2%) 
from group 2 restarted treatment with epoetin alfa. 
The percentage of patients who responded was 
72.6% (45 patients) in group 1 and 66.7% 
(42 patients) in group 2 (p = 0.3).395
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The mean treatment duration with the study 
drug was 6.47 ± 4.09 weeks in group 1 and 6.5 ± 
4.1 weeks in group 2 (p = 0.923). The erythropoi-
etic agent total average dose administered in each 
group was of 970.5 mcg for darbopoetin alpha and 
260,000 UI for epoetin alpha respectively. The 
reason for termination of treatment with the study 
drug are presented in Table 2.
One month after the ﬁ  nal dose of the epoetin 
alfa or darbepoetin alfa, the mean Hb levels were 
14.25 ± 1.08 g/dL, an increase of 2.21 g/dL over 
baseline, in group 1 and 14.3 ± 1.35 g/dL, an 
increase of 2.46 g/dL over baseline, in group 2 
(p = 0.440).
The Hb levels at the start of RT or RCT treatment 
was 13.01 ± 1.43 g/dL in group 1 and 12.7 ± 
1.77 g/dL in group 2 (p = 0.461) and at the end of 
RT or RCT were 13.47 ± 1.69 g/dL and 13.2 ± 
1.89 g/dL, respectively (p = 0.415).
Thirty-four adverse events (27,4% in group 1 
and 27% in group 2, p = 0.558) were observed. 
Most adverse events were related to the tumor 
progression or the oncological treatment. However, 
4 adverse events (2 in each treatment group) were 
vascular and may have been related to the admin-
istration of the study drug: 1 thrombophlebitis 
event, 2 acute myocardial infarction events, and 1 
aortic aneurysm rupture. All events except 
Table 1. Descriptive characteristics of the sample.
Treatment group  Group 1 Group 2 P
Number of patients N = 62 N = 63
Age (mean ± SD) 67.89 ± 11.8 66.84 ± 10.78 0.606
Sex males 45 (72.6%) 39 (61.9%) 0.140
females 17 (27.4%) 24 (38.1%)
Tumor H&N 15 (24.2%) 19 (30.2%) ns
Breast 5 (8.1%) 4 (6.3%)
Rectum 11 (17.7%) 10 (15.9%)
Genitourinary 15 (24.2%) 14 (23.8%)
Lung 4 (6.5%) 4 (6.5%)
Gynecologic 5 (8.1%) 5 (8.1%)
Esophagogastric 3 (4.8%) 3 (4.8%)
Other 4 (6.5%) 3 (4.8%)
Stage I 3 (4.8%) 10 (15.9%) 0.124
II 24 (38.7%) 15 (23.8%)
III 27 (43.5%) 31 (49.2%)
IV 4 (6.5%) 5 (7.9%)
Tumor recurrence 3 (98.4%) 1 (1.6%)
Not stated 1 (1.6%) 1 (1.6%)
Previous oncological
treatment
Neoadjuvant CTX 8 (12.9%) 8 (12.7%) 0.592
Surgery 26 (41.9%) 29 (46%) 0.359
Adjuvant CTX 5 (8.1%) 8 (12.7%) 0.280
HT 9 (14.5%) 7 (11.1%) 0.408
Current oncological
treatment
RT + CTX 20 (32.3%) 24 (38.1%) 0.664
RT only 42 (67.7%) 39 (61.9%)
Intention to treat with RT Radical 35 (56.5%) 32 (50.8%) 0.850
Adjuvant 19 (30.6%) 24 (38.1%)
Neoadjuvant 6 (9.7%) 5 (7.9%)
Palliative 2 (3.2%) 2 (3.2%)396
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thrombophlebitis resulted in death. Blood pressure 
was controlled weekly during the study and showed 
no marked changes.
The mean levels of serum iron, ferritin, and % 
saturation are shown in Table 3.
Discussion
Recombinant HuEPO is useful in the treatment of 
anemia, increasing the hemoglobin levels and 
reducing the need for transfusion in patients with 
chronic anemia due to cancer. It also improves the 
quality of life and the performance status and is 
well tolerated (16,17). The best results have been 
obtained by subcutaneous administration (18). The 
standard dose of epoetin alfa in cancer patients is 
150 IU/kg, 3 times per week, doubling the dose if 
the Hb levels have not increased at least 1 g/dL 
after 4 weeks of treatment. However, pharmaco-
kinetic and pharmacodynamic studies have dem-
onstrated equivalence between a weekly regimen 
of 40,000 IU and a thrice weekly regimen of 
150 IU (19). In 2001, Gabrilove et al. (20), pub-
lished the results from 3012 non-hematologic 
cancer patients undergoing chemotherapy treat-
ment who were also receiving epoetin alfa at doses 
of 40,000 IU/week. The dose was increased to 
60,000 IU/week if no response was obtained after 
4 weeks. This once weekly regimen increased the 
Hb levels, reduced the transfusion requirements, 
and improved the quality of life in patients with 
cancer and anemia who were receiving chemo-
therapy. The results were similar to those seen 
when a three times a week regimen was used.
Figure 1. Changes in the Hb over the course of the study.
Table 2. Reason for the termination of treatment with the study drug.
Reason for termination, n (%) Group 1 (Darbepoetin alfa) Group 2 (Epoetin alfa)
Achieved a Hb   15 g/dL during RT or RCT 20 (65.6%) 20 (65.6%)
Hb 14 g/dL after RCT treatment 23 (38.3%) 17 (27.4%)
Completed 16 weeks of study drug 4 (6.7%) 1 (1.6%)
Study drug related or unrelated adverse event 12 (19.7%) 18 (29.0%)
Patient request 4 (6.8%) 7 (11.3%)
2 patients in each group required RBC transfusions.
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Darbepoetin alfa, with its higher concentration 
of sialic acid, has a longer mean half-life than other 
epoetins. Several randomized studies have dem-
onstrated its efﬁ  cacy and tolerance in the control 
of anemia induced by chemotherapy in patients 
with lymphoproliferative diseases (21) and in those 
with solid tumors (15) when given weekly or three 
times a week (22).
In our study, we have used the guideline of 
administration of weekly erythropoietic agent, 
since the obtained results are equal to the obtained 
ones with regimes of three days per week and the 
quality of life of the patient is improved. Oral iron 
was administered to all the patients since the cor-
rection of the anemia is faster when the erythrpoi-
etic agents goes along with iron administration.
Although a number of publications discuss the 
efﬁ  cacy and safety of the 2 erythropoietic agents, 
few publications compare the two. We have found 
only 2 retrospective studies comparing epoetin alfa 
and darbepoetin alfa.
The study by Reeves et al. (23,24) provides a 
retrospective analysis of 512 patients with 
chemotherapy-induced anemia who received treat-
ment with erythropoietic agents: 196 patients 
received darbepoetin alfa, 212 patients received 
epoetin alfa, and 104 patients received both agents. 
Darbepoetin alfa was most frequently given in 
doses of 100 mcg/week and 200 mcg/2 weeks (49% 
and 36%, respectively, 300 patients) and 86% of 
the 212 patients on epoetin alfa received 40,000 
IU/week. The mean baseline Hb was 10.1 g/dL for 
the darbepoetin alfa group and 9.6 g/dL for the 
epoetin alfa group. Reeves et al. analyzed the 
results from 350 patients (a separate analysis); 97 
patients were treated with darbepoetin alfa 100 
mcg/week, 70 patients were treated with darbepo-
etin alfa 200 mcg/2 weeks, and 183 patients were 
treated with epoetin alfa 40,000 IU/week. The 
respective increases in the Hb at 5 weeks were 0.8 
g/dL, 0.8 g/dL and 0.6 g/dL and, at 8 weeks, the 
increases were 1.1 g/dL, 1.3 g/dL, and 0.9 g/dL. 
The incidence of transfusions was 4%, 11%, and 
14%, respectively. The conclusion of the study was 
that darbepoetin alfa and epoetin alfa have a com-
parable efﬁ  cacy in the treatment of chemotherapy-
induced anemia.
The second study, published by Herrington, 
et al. (25), retrospectively reviewed 3123 medical 
histories from 65 oncology hospitals and selected 
1444 patients who were treated with darbepoetin 
alfa and 1341 who were given epoetin alfa over 12 
weeks. In 61% of the patients who received dar-
bepoetin alfa, the dose used was 200 mcg/2 weeks, 
and in 72% of the patients who received epoetin 
alfa the dose was 40,000 IU/week. Baseline Hb 
Table 3. Mean serum iron, ferritin, and % saturation levels.
Level Group 1 (Darbepoetin alfa) Group 2 (Epoetin alfa) P
Serum Iron, mcg/dL (mean ± SD)
 Baseline 75.71 ± 45.56 82.16 ± 49.23 0.456
 Week  4 65.35 ± 57.87 67.73 ± 48.11 0.831
 Week  12 34.09 ± 8.74 67.30 ± 64.05 0.104
  1 month after ﬁ  nal dose of study drug 99.15 ± 41.28 113.04 ± 45.43 0.186
Ferritin, ng/mL (mean ± SD)
 Baseline 255.10 ± 250.86 245.12 ± 324.88 0.851
 Week  4 149.66 ± 212.08 144.41 ± 233.54 0.911
 Week  12 192.18 ± 413.35 97.0 ± 199.16 0.517
  1 month after ﬁ  nal dose of study drug 246.55 ± 280.76 291.90 ± 285.28 0.510
Saturation,% (mean ± SD)
 Baseline 31.98 ± 25.05 34.37 ± 27.93 0.618
 Week  4 27.44 ± 32.76 25.93 ± 23.32 0.800
 Week  12 13.54 ± 5.3 24.9 ± 32.12 0.261
  1 month after ﬁ  nal dose of study drug 41.65 ± 27.87 44.64 ± 22.43 0.631398
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was 10.3 g/dL in both groups. The dose was 
increased in 22% of the patients treated with dar-
bepoetin alfa and in 23% of those treated with 
epoetin alfa after a mean period of 6 weeks in each 
group. The transfusion requirements were also 
similar in the 2 groups: 11% in the darbepoetin alfa 
group and 12% in the epoetin alfa group. After 12 
weeks of treatment, the increase in Hb was 1.0 g/dL 
in the darbepoetin group and 1.1 g/dL in the epo-
etin alfa group. Harrington et al. concluded that at 
the doses used (darbepoetin alfa 200 mcg/2 weeks 
and epoetin alfa 40,000 IU/week) the efﬁ  cacy is 
clinically comparable.
In our series, the Hb at the beginning of the 
treatment with erythropoietic agent is 11.85 + 1.125 
for group 1 and 11.76 + 1.138 for group 2; superior 
to the one of the studies commented previously; 
nevertheless our results, with respect to the increase 
and maintenance of the levels of Hb, are superpos-
able to the obtained ones by them.
Schwartzberg et al. (26) published the results 
of a randomized study in 312 patients with breast, 
lung and gynecological cancer who had chemo-
therapy-induced anemia; 157 patients received 
darbepoetin alfa 200 mcg/2 weeks and 155 
patients received epoetin alfa 40,000 IU/week. 
Overall, no signiﬁ  cant differences were observed 
in the analysis of:
•  mean baseline Hb (10.4 g/dL in both groups),
•    the percentage of patients who reached Hb 
levels  11 g/dL (82% vs 86%),
•    the mean time in which Hb   11 g/dL was 
achieved (5 vs 4 weeks),
•   the duration of treatment with the erythropoietic 
treatment (9.3 vs 10.1 weeks),
•   the Hb level achieved during the study (12.1 vs 
12.2 g/dL),
•  the increase in Hb (1.8 vs 1.6 g/dL),
•    the transfusion requirements (16% vs 17%), or
•  or the adverse effects related to the treatment.
This study concluded that darbepoetin alfa 
(200 mcg/2 weeks) and epoetin alfa (40,000 IU/
week) have comparable clinical efﬁ  cacy.
At the American Society of Clinical Oncology 
(ASCO) 41st Annual Meeting in 2005, the ﬁ  nal 
results of 2 randomized studies comparing darbe-
poetin alfa (200 mcg/2 weeks) and epoetin alfa 
(40,000 IU/week) in patients with chemotherapy 
induced anemia, with contradictory results, were 
presented. In the study conducted by Waltzman 
et al. (27), 180 patients receiving darbepoetin alfa 
and 178 patients receiving epoetin alfa had a 
baseline Hb of 10.1 and 10.2 g/dL, respectively. 
The Hb increase at the end of the study was sig-
niﬁ  cantly higher in the epoetin alfa group (0.8 vs 
1.2 g/dL), the mean time to increase the Hb level 
by 1 g/dL was signiﬁ  cantly lower in the epoetin 
group (48 vs 35 days), and the percentage of 
patients with an increase in Hb  2 g/dL was sig-
niﬁ  cantly higher in the epoetin alfa group (26% vs 
44% at 9 weeks and 41% vs 57%) at the end of the 
study. It was concluded that the index of response 
is greater and the time to achieve an increase in Hb 
of 1 g/dL is shorter in the group treated with epo-
etin alfa 40,000 IU/week compared with darbepo-
etin alfa 200 mcg/2 weeks. In the second study, 
Glaspy et al. (28) randomized 1220 patients, 1209 
of which received more than one dose of study 
drug (606 patients received darbepoetin alfa 
200 mcg/2 weeks and 603 received epoetin alfa 
40,000 IU/week). The mean levels of baseline Hb 
were 10.2 g/dL in both groups. No signiﬁ  cant dif-
ferences were found in:
•    the mean Hb at the end of the study (11.8 and 
11.9 g/dL),
•    the percentage of patients who achieved a Hb 
level between 11 and 13 g/dL (76% vs 81%),
•    the mean time to achieve a Hb level between 
11 to 13 g/dL (6 vs 5 weeks),
•    the percentage of patients who maintained a Hb 
level between 11 to13 g/dL (74% vs 80%), and
•  the transfusion requirements (21% vs 16%).
The authors concluded the adverse effects were 
also similar between the groups and that both 
agents present similar clinical efﬁ  cacy.
In Europe, the usual administration of darbepo-
etin alfa is 150 mcg/week, although the optimal 
dose of darbepoetin alfa given weekly and its 
therapeutically equivalent dose with epoetin alfa 
(29) are not yet clearly deﬁ  ned.
We have not found any published study compar-
ing the efﬁ  cacy of both drugs in weekly administra-
tion. In our study, we prospectively included 
125 consecutive patients receiving RT or RCT with 
anemia, deﬁ  ned as Hb   13 g/dL in males and  12 
g/dL in females. The mean Hb level at study drug 
initiation was 11.85 g/dL in the darbepoetin alfa 
group and 11.76 g/dL in the epoetin alfa group 
(p = ns). After 4 weeks of treatment, the Hb levels 
increased in both groups to 13.16 g/dL in the dar-
bepoetin alfa group and to 13.02 g/dL in the epo-
etin alfa group (p = ns). Of the patients treated with 399
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darbepoetin alfa, 19.4% doubled the dose compared 
with 23.8% in the epoetin alfa group (p = ns). The 
increases in the mean levels of Hb over the baseline 
values one month after the ﬁ  nal dose were 2.21 
g/dL and 2.46 g/dL, respectively (p = ns). The 
transfusion requirements were similar in the 2 
groups. These dates demonstrate the efﬁ  cacy of 
darbepoetin alpha and epoetin alpha in increasing 
Hb levels and agree with Reeves et al. (24) and 
Herrington et al. (25), in demonstrating a similar 
clinical effectiveness for both erythropoietic 
agents. Changes regarding Hb intervention values 
have been published as guidelines (30) for the last 
few years; this study stands for march 2003 stan-
dards and does not match with actual clinical 
practice.
Conclusions
The results of our study demonstrate that the 2 
treatments, darbepoetin alfa 150 mcg/week and 
epoetin alfa 40,000 IU/week, are equally effective 
in correcting anemia in cancer patients receiving 
RT or RCT treatment.
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